SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

Assessing the effectiveness of human papillomavirus (HPV) vaccination to prevent cervical cancer: perspectives from Germany

By Leave a Comment

J Epidemiol Community Health

February 2010 Vol 64 No 2

For approximately 2 years now, cervical cancer has been “converted” from an oncological disease to an infectious disease, which is said to be preventable by and large by two vaccines licensed in many countries. However, human papillomavirus (HPV) vaccines differ from existing others, as the former target
a condition which only in a minute fraction of infections will lead to serious consequences, but after a long(er) latency period. Furthermore, it should be kept in mind that in clinical trials, the quadrivalent vaccine was tested in fewer than 1200 girls 16 years and younger.1

Warning All Pregnant Women: Miscarriages From H1N1 Vaccine As High As 3,587 Cases

By Leave a Comment

Prevent Disease

A shocking report from the National Coalition of Organized Women (NCOW) presented data from two different sources demonstrating that the 2009/10 H1N1 vaccines contributed to an estimated 1,588 miscarriages and stillbirths. A corrected estimate may be as high as 3,587 cases. NCOW also highlights the fact that the CDC failed to inform their vaccine providers of the incoming data of the reports of suspected H1N1 vaccine related fetal demise. NCOW collected the data from pregnant women (aged 17 to 45) that occurred after they were administered a 2009 A-H1N1 flu vaccine.The raw data is available on the ProgressiveConvergence.com website

Using the Vaccine Adverse Event Reporting System (VAERS), including updates through July 11, 2010 as a second ascertainment source, capture-recapture statistical methods were used to estimate the true number of miscarriages and stillbirths following A-H1N1 flu vaccination in the U.S.

Parents Warn of HPV Vaccine Dangers

By Leave a Comment

The Epoch Times

By Susanne Larsson
Epoch Times Staff
Sweden

Despite thousands of young girls’ accounts of severe side effects from Gardasil injections, the manufacturer, Merck & Co, Inc., continues to make and sell the vaccine, which is supposed to protect against cervical cancer. Now the girls’ parents warn about the vaccine on their own websites.

According to Natural News Magazine, the Food and Drug Administration (FDA) approved Gardasil for the American market in 2006, and by February 2009, more than 40 million doses had been distributed worldwide.

Gardasil is a vaccine that’s supposed to prevent cervical cancer caused by the human papilloma virus (HPV). The virus spreads through sexual intercourse or skin contact.

September 2, 2010 Approval Letter – Cervarix

By Leave a Comment

FDA – US food and Drug Administration

DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration
Rockville, MD 20852-1448

Our STN: BL 125259/98

GlaxoSmithKline Biologicals
Attention: Matthew Whitman
2301 Renaissance Boulevard
P.O. Box 61540
King of Prussia, PA 19406-2772

Dear Mr. Whitman:

We have approved your request to supplement your biologics license application for Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant, to add lymphadenopathy to the Adverse Reactions, Postmarketing Experience section of the full prescribing information.

Inovio Pharmaceuticals Achieves Unprecedented T-Cell Immune Responses in Human Trial of DNA Vaccine for Cervical Dysplasia and Cancer Caused by HPV

By Leave a Comment

DNA Vaccine Delivered Using Electroporation Shows Potential to Treat Cervical Cancer and Precursor Dysplasias; Vaccine to Start Phase II in Early 2011
Market Watch

BLUE BELL, Pa., Sep 13, 2010 (BUSINESS WIRE) — Inovio Pharmaceuticals, Inc. /quotes/comstock/14*!ino/quotes/nls/ino (INO 1.11, 0.00, 0.00%) , a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18. This vaccine targets HPV E6 and E7 proteins and is delivered via in vivo electroporation. All dose groups developed significant antibody and T-cell immune responses; however, more notably, in the third and final dose group, five of six (83%) patients developed unprecedented T-cell responses not achieved by any other non-replicating vaccine platform in humans. Inovio is planning to start a Phase II clinical study in the first quarter of 2011.

News

Videos

Contact